Number of the records: 1
Novel glutamine antagonists and uses thereof
- 1.
SYSNO ASEP 0580592 Document Type P - Patent R&D Document Type Patent or other outcome protected by special legislation Title Novel glutamine antagonists and uses thereof Author(s) Slusher, B. (US)
Rais, R. (US)
Majer, Pavel (UOCHB-X)
Tenora, Lukáš (UOCHB-X) ORCID
Novotná, Kateřina (UOCHB-X) ORCID
Alt, J. (US)Year of issue 2022 Possible third party use of the result A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence Royalty requested A - Poskytovatel licence požaduje licenční poplatek Patent no. or utility model no. or industrial design no. EP3692015 Date of the patent acceptance 24.08.2022 Name of the patent owner The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR, v. v. i Code of the issuer name EPO_1 - European Patent Office Munich, The Hague, Berlin, Vienna, Brusselshttp://www.epo.org/ Current use B - Patent je využíván na základě uzavřené licenční smlouvy mezi vlastníkem a uživatelem Territorial Protection EPC - evropský patent podle Evropské patentové úmluvy
PCT - mezinárodní patentová ochrana dle Smlouvy o patentové spolupráciLanguage eng - English Keywords glutamine antagonists ; 6-diazo-5-oxo-L-norleucine ; prodrug strategies OECD category Organic chemistry R&D Projects LTAUSA18166 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) Institutional support UOCHB-X - RVO:61388963 Annotation Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Workplace Institute of Organic Chemistry and Biochemistry Contact asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418 Year of Publishing 2024 Electronic address https://worldwide.espacenet.com/patent/search/family/065994832/publication/EP3692015B1?q=EP3692015B1
Number of the records: 1